Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc. develops clinical-stage biotechnology programs for hematologic diseases, led by burixafor (GPC-100), a highly selective small-molecule CXCR4 antagonist. Company updates center on burixafor's role in hematopoietic stem cell mobilization for multiple myeloma transplant settings, sickle cell disease, cell and gene therapy support, and acute myeloid leukemia chemosensitization.
Recurring news also covers clinical data presentations and publications, collaborations for combination approaches, financial results, liquidity disclosures, and research spending following Exicure's acquisition of GPCR Therapeutics USA. Earlier company context includes its historical focus on nucleic acid therapies and restructuring before the current hematology-focused pipeline.
Exicure, Inc. (NASDAQ: XCUR) has received Fast Track designations from the FDA for cavrotolimod (AST-008) targeting advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma, both refractory to prior therapies. Cavrotolimod enhances immune responses and is currently in a Phase 1b/2 trial, showing a 21% overall response rate in evaluable patients, including durable responses exceeding six months. No serious adverse events were reported, and significant immune cell activation was observed. This designation highlights the urgent need for novel therapies in these cancer types.
Exicure, Inc. (NASDAQ: XCUR) has appointed James Sulat to its Board of Directors, bringing extensive biopharmaceutical experience. Sulat has held leadership roles at various firms and currently serves on the boards of Valneva SE and Arch Therapeutics. His background in business development and finance is expected to support Exicure's growth. Additionally, Jay Venkatesan has resigned from the Board, effective December 29, 2020. The company focuses on gene regulatory therapies targeting cancer and genetic disorders using its proprietary SNA™ technology, with its lead program in a Phase 1b/2 trial.
Exicure, Inc. (NASDAQ: XCUR) will host a virtual R&D Day on January 7, 2021, to discuss its neuroscience pipeline, focusing on its lead program for Friedreich’s Ataxia (FA). The company reported that XCUR-FXN has moved into IND-enabling studies, with updates on other preclinical programs targeting SCN9A for neuropathic pain and CLN3 for Batten Disease. Exicure will showcase CNS biodistribution studies of its SNA™ therapeutics. Despite the absence of therapies for FA, the meeting aims to engage stakeholders in discussions about future clinical developments.
Exicure, Inc. (Nasdaq: XCUR) announced that CEO David Giljohann will present at the HC Wainwright Virtual BIOCONNECT Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 AM EST via the conference link. Exicure focuses on gene regulatory and immunotherapeutic drugs utilizing its proprietary Spherical Nucleic Acid (SNA™) technology. Currently, the company is developing candidates for Friedreich’s ataxia and has a drug in a Phase 1b/2 clinical trial for advanced solid tumors.
Exicure, Inc. (NASDAQ: XCUR) has announced a virtual R&D Day on January 7, 2021, from 09:00 am to 10:30 am ET. This event will showcase the company's neuroscience pipeline, particularly its lead program targeting Friedreich’s Ataxia, which has moved into IND-enabling studies. Participants include Dr. Susan Perlman and Jennifer Farmer, who will discuss advancements in the program. Exicure is focused on developing therapeutics using its proprietary SNA technology to address various conditions, including genetic disorders.
Exicure, Inc. (Nasdaq: XCUR) has strengthened its intellectual property portfolio with the issuance of two new patents and the allowance of a patent application related to its therapeutic candidate, cavrotolimod. The new patents (No. 10,792,251 and No. 10,837,018) cover innovative spherical nucleic acid constructs for cancer treatment. CEO David Giljohann expressed enthusiasm about cavrotolimod, currently in Phase 2 clinical trials for Merkel cell carcinoma and cutaneous squamous cell carcinoma, indicating its potential to address unmet medical needs in these rare skin cancers.
Exicure, Inc. (NYSE American:XCUR) will present at the virtual Fall Investor Summit from November 16-18, 2020. This event includes 75 companies and over 300 institutional and retail investors. Exicure focuses on developing nucleic acid-based therapeutics for rare genetic diseases and cancer. Their proprietary spherical nucleic acid (SNA) technology aims to improve drug efficacy across various cells and tissues. The conference connects smallcap and microcap companies with qualified investors, offering a platform for valuable networking.